You are here: Home » News-ANI » Business
Business Standard

Cell therapy options at Guang-Li Biomedicine and Taipei Medical University Hospital bring hope to cancer patients

Topics
Health Medical Pharma

ANI 

The immunotherapy used by Guang-Li Biomedicine and Taipei Medical University Hospital brings new hope to the terminal patients of solid cancer.

The international journals Cell and Science have reported that immune cell therapy is a new generation of anti-cancer weapons. The immuno-cell therapy developed by Guang-Li Biomedicine and Taipei Medical University Hospital uses the human body's immune system to attack tumour cells. This major breakthrough in cancer treatment has prolonged the life of many cancer patients who were previously incurable and even cured them.

With cell therapy officially allowed in Taiwan, Guang-Li Biomedicine and Taipei Medical University Hospital are leading Taiwan's many medical institutions and research units in legalizing cancer treatment programs. The Guang-Li Experimental Center took advantage of stem cell storage patents and immune cell preparation technology and successfully submitted application and received approval of CIK immune cell therapy for 12 solid cancers, bringing top medical technology to patients.

"The clinical trial of the hospital and Guang-Li Biomedicine has been approved. Highly active Cytokine-induced killer cells (CIK) can be used on first-to third-stage cancer patients that do not respond to treatment effects, as well as patients in the fourth phase of solid cancer, which is currently a more effective way to prolong life and cure cancer than other therapies", said Lee, Kuan-Der, deputy dean of Taipei Medical University Hospital.

The indication of approved projects includes colorectal cancer, breast cancer, lung cancer, cervical cancer, ovarian cancer, kidney cancer, liver cancer, pancreatic cancer, nasopharyngeal cancer, stomach cancer, oesophageal cancer, and cholangiocarcinoma.

In the past, cancer treatment, regardless of surgery, chemotherapy, radiation therapy, is to remove tumor cells from the outside, but Taiwanese law already allows the use of autologous cells for autoimmune cell therapy, and there are many successful cases for patients with stable cancer. In addition, Taiwan has also opened up autologous chondrocyte transplantation, autologous fat stem cell transplantation, skin repair, wound healing, and articular cartilage regeneration.

This story is provided by Digpu. ANI will not be responsible in any way for the content of this article.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, December 02 2019. 12:07 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU